FDA Accepts NDA for Ibrutinib for Two Non-Hodgkin's Subtypes

Pharmacyclics, Inc. announced at the end of last week that the U.S. Food and Drug Administration (FDA) had accepted their New Drug Application (NDA) for filing for the investigational oral Bruton's tyrosine kinase (BTK) inhibitor ibrutinib, for two B-cell malignancy indications: previously treated mantle cell lymphoma (MCL) and previously treated chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL).

Back at the end of June, Pharmacyclics submitted a New Drug Application (NDA) for ibrutinib under section 505(b) of the Food, Drug & Cosmetic Act.

Pharmacyclics learned on 27 August that the FDA had completed their filing review and determined that the application is sufficiently complete to permit a substantive review.

Said Dr. Urte Gayko, Senior Vice President of Global Regulatory Affairs for Pharmacyclics:

We are very excited to have received the official FDA acceptance of our first NDA filing for ibrutinib. We look forward to continuing to work with the FDA as they complete their review of the ibrutinib application which includes the new Breakthrough Therapy Designation process.

Each year, about 16,000 new cases of CLL/SLL are diagnosed in the United States, while about 2,500 new cases of mantle cell lymphoma are diagnosed.

Source: WSJ

More Articles

More Articles

According to a study by Japanese researchers, the SMILE combination chemotherapy protocol is effective against extranodal natural killer/T-cell...

Patients treated with maintenance rituximab had three times longer progression-free survival. This is a summary of an article published in the...

When you consider that the adult human body has anywhere from 300 to 700 lymph nodes, the better question might not be where ARE they located, but...

This entry looks at a non-Hodgkin's lymphoma called true histiocytic lymphoma (THL), also referred to as diffuse histiocytic lymphoma, and...

Lymphomatous meningitis [LM], also known as leukemic meningitis, is an extremely serious peripheral cancer that attacks the tissue that covers the...

Hodgkin's Disease—also referred to as Hodgkin's Lymphoma, these are the exact same diseases, just...

Intravascular lymphoma is a subtype of 'Lymphoma', an umbrella term that loosely refers to several dozen...

While the average lifespan for hamsters is only about 2.5 years, and they are therefore less prone to long-term illnesses, it is possible for a...

Burkitt's lymphoma is an aggressive B-cell lymphoma that is common in children...

Lymphoma is a cancer of the lymphatic system, causing B-cell or...

The term NK T cell lymphoma refers to one of two subtypes of lymphoma that affect the NK (Natural Killer)...

Lymphoma is a life-threatening disease, but is very treatable in most cases. The 5-year survival for patients diagnosed with non-Hodgkin's...

T cell lymphoma treatment options for these cancers are not especially effective and there is no absolute consensus about optimal treatments for...

Marginal zone lymphomas (MZL) are indolent lymphomas that affect the B-cells. The...

Lymphomas can arise from most any lymphatic tissue (lymph nodes, spleen, thymus, mucosa associated lymphoid...